|
humans |
51 |
|
male |
47 |
|
adult |
45 |
|
female |
45 |
|
middle aged |
42 |
|
covid-19 |
37 |
|
medical sciences |
34 |
|
aged |
31 |
|
bronchiectasis |
25 |
|
hong kong |
23 |
|
sars-cov-2 |
20 |
|
obstructive sleep apnea |
19 |
|
body mass index |
18 |
|
chronic obstructive pulmonary disease |
18 |
|
copd |
18 |
|
lung cancer |
18 |
|
asthma |
17 |
|
hong kong - epidemiology |
17 |
|
obesity |
16 |
|
respiratory diseases |
16 |
|
cross-sectional studies |
15 |
|
risk factors |
15 |
|
asian continental ancestry group |
14 |
|
complications |
14 |
|
coronavirus infection |
14 |
|
enzyme-linked immunosorbent assay |
14 |
|
health outcomes |
14 |
|
prospective studies |
14 |
|
polysomnography |
13 |
|
prognosis |
13 |
|
tomography, x-ray computed |
13 |
|
cohort studies |
12 |
|
covid-19 vaccines |
12 |
|
innate immunity |
12 |
|
prevalence |
12 |
|
retrospective studies |
12 |
|
tuberculosis |
12 |
|
adolescent |
11 |
|
case-control studies |
11 |
|
chemotherapy |
11 |
|
forced expiratory volume |
11 |
|
age factors |
10 |
|
child |
10 |
|
chinese |
10 |
|
cigarette smoke |
10 |
|
logistic models |
10 |
|
lung function |
10 |
|
obstructive sleep apnoea |
10 |
|
sensitivity and specificity |
10 |
|
smoking |
10 |
|
treatment outcome |
10 |
|
adiponectin |
9 |
|
c-reactive protein |
9 |
|
chest x-ray |
9 |
|
china - ethnology |
9 |
|
cigarette smoking |
9 |
|
endothelial function |
9 |
|
hospitalization |
9 |
|
magnetic resonance imaging |
9 |
|
metabolic syndrome |
9 |
|
nomogram |
9 |
|
nonrestorative sleep |
9 |
|
prediction model |
9 |
|
pseudomonas aeruginosa |
9 |
|
reliability |
9 |
|
sleep apnea |
9 |
|
statistics, nonparametric |
9 |
|
vital capacity |
9 |
|
white cell count |
9 |
|
adiponectin - blood |
8 |
|
bronchiectasis exacerbation |
8 |
|
catalase |
8 |
|
cephalometry |
8 |
|
child, preschool |
8 |
|
chronic kidney disease |
8 |
|
continuous positive airway pressure |
8 |
|
eosinophil |
8 |
|
item response theory |
8 |
|
item selection |
8 |
|
optimal test assembly |
8 |
|
pemetrexed |
8 |
|
phenotype |
8 |
|
superoxide dismutase |
8 |
|
sympathetic activity |
8 |
|
anti-inflammatory agents - pharmacology |
7 |
|
anxiety |
7 |
|
atherosclerosis |
7 |
|
biomarkers |
7 |
|
body composition - physiology |
7 |
|
body height |
7 |
|
confirmatory factor analysis |
7 |
|
coping |
7 |
|
corticosteroid |
7 |
|
depression |
7 |
|
down-regulation - physiology |
7 |
|
drug modulation |
7 |
|
incidence |
7 |
|
insomnia |
7 |
|
interleukin-6 |
7 |
|
intermittent hypoxia |
7 |
|
intra-abdominal fat - physiopathology |
7 |
|
lung - physiopathology |
7 |
|
mental health |
7 |
|
molnupiravir |
7 |
|
oxidative stress |
7 |
|
probability |
7 |
|
reference values |
7 |
|
regression analysis |
7 |
|
sex factors |
7 |
|
sleep apnea, obstructive - diagnosis - physiopathology |
7 |
|
subcutaneous fat, abdominal - physiopathology |
7 |
|
sympathetic nervous system - physiopathology |
7 |
|
up-regulation |
7 |
|
validity |
7 |
|
acute disease |
6 |
|
advanced glycation end-products |
6 |
|
aged, 80 and over |
6 |
|
airway epithelial cells |
6 |
|
anti-inflammatory agents - administration & dosage |
6 |
|
bifactor |
6 |
|
biological markers - analysis |
6 |
|
blood pressure |
6 |
|
bronchial epithelial cells |
6 |
|
bronchiectasis - metabolism |
6 |
|
bronchiolitis obliterans syndrome |
6 |
|
c-reactive protein - analysis |
6 |
|
cells, cultured |
6 |
|
circadian rhythm |
6 |
|
comorbidity |
6 |
|
curriculum |
6 |
|
epithelial cells |
6 |
|
erythrocytes - enzymology |
6 |
|
erythromycin |
6 |
|
follow-up studies |
6 |
|
forced expiratory volume - physiology |
6 |
|
gefitinib |
6 |
|
glutathione peroxidase |
6 |
|
graft versus host disease |
6 |
|
haematopoietic stem cell transplantation |
6 |
|
insulin - metabolism |
6 |
|
insulin sensitivity |
6 |
|
interleukin-6 - biosynthesis |
6 |
|
intra-abdominal fat |
6 |
|
lung function decline |
6 |
|
methylprednisolone - administration & dosage |
6 |
|
quality of life |
6 |
|
questionnaires |
6 |
|
respiratory function tests |
6 |
|
ribavirin - therapeutic use |
6 |
|
sleep apnea syndromes - complications - physiopathology |
6 |
|
sleep apnea, obstructive - metabolism |
6 |
|
spirometry |
6 |
|
sputum |
6 |
|
survival |
6 |
|
visceral fat |
6 |
|
waist circumference |
6 |
|
actigraphy |
5 |
|
acute exacerbation |
5 |
|
acute kidney injury |
5 |
|
adenocarcinoma - diagnosis - pathology |
5 |
|
administration, inhalation |
5 |
|
alertness |
5 |
|
anthropometry |
5 |
|
antigens, cd56 - biosynthesis |
5 |
|
antiviral agents - therapeutic use |
5 |
|
asian continental ancestry group - genetics |
5 |
|
aspergillus - isolation & purification |
5 |
|
asthma - drug therapy |
5 |
|
autofluorescence bronchoscopy |
5 |
|
azithromycin |
5 |
|
biological markers - blood |
5 |
|
bone density - drug effects |
5 |
|
bone marrow transplantation - adverse effects |
5 |
|
bronchiolitis obliterans syndrome (bos) |
5 |
|
carcinoma, non-small-cell lung - blood - genetics - pathology |
5 |
|
carcinoma, squamous cell - diagnosis - pathology |
5 |
|
carcinoma, squamous cell - diagnosis - therapy - ultrasonography |
5 |
|
cell apoptosis (细胞凋亡) |
5 |
|
china |
5 |
|
chronic obstructive (慢性阻塞性) |
5 |
|
communication |
5 |
|
coronavirus disease 2019 |
5 |
|
cytological techniques |
5 |
|
disease outbreaks |
5 |
|
disease progression |
5 |
|
dna, neoplasm - blood - genetics |
5 |
|
dose-response relationship, drug |
5 |
|
double-blind method |
5 |
|
drug therapy, combination |
5 |
|
early detection |
5 |
|
education, medical, undergraduate - methods |
5 |
|
egfr array |
5 |
|
endobronchial ultrasound |
5 |
|
endothelial progenitor cells |
5 |
|
epidemiology |
5 |
|
epidermal growth factor receptor |
5 |
|
facemask |
5 |
|
follow-up |
5 |
|
fusarium |
5 |
|
genotype |
5 |
|
hematopoietic sct (hsct) |
5 |
|
hilar lymphadenopathy |
5 |
|
inflammatory effect (炎症反应) |
5 |
|
insulin resistance - physiology |
5 |
|
international students |
5 |
|
interstitial lung disease |
5 |
|
linear models |
5 |
|
longitudinal studies |
5 |
|
lung |
5 |
|
lung neoplasms - diagnosis - pathology |
5 |
|
lung neoplasms - diagnosis - therapy - ultrasonography |
5 |
|
lymph nodes - pathology |
5 |
|
masks |
5 |
|
metabolic syndrome x - complications - physiopathology |
5 |
|
mutation - genetics |
5 |
|
nasal continuous positive airway pressure |
5 |
|
neoplasm staging |
5 |
|
nirmatrelvir-ritonavir |
5 |
|
nirmatrelvir–ritonavir |
5 |
|
noise |
5 |
|
noise sensitivity |
5 |
|
non-small-cell lung cancer |
5 |
|
obstructive pulmonary disease (阻塞性肺疾病) |
5 |
|
physician-patient relations |
5 |
|
plasma egfr mutations |
5 |
|
plethysmography |
5 |
|
polymorphism, genetic |
5 |
|
prejudiced attitudes |
5 |
|
problem solving |
5 |
|
problem-based learning - methods |
5 |
|
pulse therapy, drug - methods |
5 |
|
radiography, thoracic |
5 |
|
receptor, epidermal growth factor - genetics |
5 |
|
ribavirin |
5 |
|
severe acute respiratory syndrome |
5 |
|
severe acute respiratory syndrome - drug therapy |
5 |
|
severe acute respiratory syndrome - epidemiology - transmission |
5 |
|
severity of illness index |
5 |
|
sleep apnea syndrome (睡眠呼吸暂停综合征) |
5 |
|
small cell carcinoma |
5 |
|
sputum - cytology |
5 |
|
sputum cytology |
5 |
|
squamous cell carcinoma |
5 |
|
stress |
5 |
|
synchronous primary lung cancer |
5 |
|
transbronchial needle aspiration |
5 |
|
tumor markers, biological - blood - genetics |
5 |
|
tyrosine kinase inhibitor therapy |
5 |
|
ultrasonography - methods |
5 |
|
united kingdom |
5 |
|
university students |
5 |
|
vaccine |
5 |
|
young adult |
5 |
|
airflow obstruction |
4 |
|
airspace enlargement |
4 |
|
analysis of variance |
4 |
|
anthropometry - methods |
4 |
|
anti-inflammatory agents, non-steroidal - pharmacology |
4 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
4 |
|
antioxidants - analysis - metabolism |
4 |
|
antioxidants - pharmacology |
4 |
|
antitubercular agents - therapeutic use |
4 |
|
apoptosis |
4 |
|
asia - epidemiology |
4 |
|
asthma control |
4 |
|
asthma exacerbation |
4 |
|
autoantibodies - analysis |
4 |
|
bacterial adherence |
4 |
|
bacterial adhesion - drug effects |
4 |
|
bacterial morphology |
4 |
|
biological availability |
4 |
|
blood glucose - analysis |
4 |
|
body weight |
4 |
|
bone marrow transplantation - adverse effects - immunology |
4 |
|
brain natriuretic peptide |
4 |
|
bronchi - immunology |
4 |
|
bronchial epithelium |
4 |
|
bronchiectasis - blood - etiology |
4 |
|
bronchiectasis - blood - physiopathology |
4 |
|
bronchiectasis - immunology |
4 |
|
bronchoscopy |
4 |
|
carcinoma, non-small-cell lung - enzymology - etiology - pathology |
4 |
|
cardiac pacing, artificial - methods |
4 |
|
catalase - analysis - metabolism |
4 |
|
catechin - analogs and derivatives - pharmacology |
4 |
|
cell transformation, neoplastic - metabolism |
4 |
|
cephalometrics |
4 |
|
chemicals and cas registry numbers |
4 |
|
chinese green tea (lung chen) |
4 |
|
chronic disease |
4 |
|
cilia |
4 |
|
collagen - physiology |
4 |
|
colonization |
4 |
|
congestive heart failure |
4 |
|
contraction |
4 |
|
cpap |
4 |
|
cpap treatment |
4 |
|
creatinine - metabolism |
4 |
|
cross-over studies |
4 |
|
crt |
4 |
|
culture media, conditioned |
4 |
|
cyclooxygenase 2 inhibitors - pharmacology |
4 |
|
diagnosis, differential |
4 |
|
education |
4 |
|
education, medical - methods - standards |
4 |
|
egfr |
4 |
|
egfr mutation |
4 |
|
egfr-tki |
4 |
|
electric impedance |
4 |
|
emphysema |
4 |
|
endothelial nitric oxide synthase |
4 |
|
epithelial cells - drug effects - immunology |
4 |
|
erythromycin - pharmacology |
4 |
|
exacerbation |
4 |
|
fatty acid-binding proteins - blood |
4 |
|
gastric-acid suppressing agents |
4 |
|
gemcitabine |
4 |
|
gene expression regulation |
4 |
|
genetic predisposition to disease |
4 |
|
genetics |
4 |
|
glutathione peroxidase - analysis - metabolism |
4 |
|
glycosylation end products, advanced - blood |
4 |
|
goblet cell |
4 |
|
goblet cells - drug effects - pathology |
4 |
|
graft vs host disease - complications - immunology |
4 |
|
health status indicators |
4 |
|
heart failure - diagnosis - prevention & control |
4 |
|
hematological toxicity |
4 |
|
hyoid bone - physiopathology |
4 |
|
hypertension |
4 |
|
hypertension, pulmonary - diagnosis - prevention & control |
4 |
|
immunosuppressive agents - pharmacology |
4 |
|
incident type 2 diabetes |
4 |
|
induced pluripotent stem cell |
4 |
|
infant |
4 |
|
infectious disease transmission, patient-to-professional |
4 |
|
influenza |
4 |
|
inhaled corticosteroid |
4 |
|
insulin resistance |
4 |
|
intercellular adhesion molecule-1 - analysis |
4 |
|
intercellular cell adhesion molecule |
4 |
|
interleukin-8 |
4 |
|
invasive mechanical ventilation |
4 |
|
kidney failure, chronic - complications - metabolism - pathology - therapy |
4 |
|
kinetics |
4 |
|
low risk |
4 |
|
lung - microbiology - pathology - radiography |
4 |
|
lung - radiography |
4 |
|
lung adenocarcinoma |
4 |
|
lung injury - drug therapy |
4 |
|
lung neoplasms - enzymology - etiology - pathology |
4 |
|
lung volume measurements |
4 |
|
maintenance chemotherapy |
4 |
|
mandible - pathology |
4 |
|
maxilla - pathology |
4 |
|
medical |
4 |
|
mesenchymal stem cell |
4 |
|
metabolic syndrome x - metabolism |
4 |
|
microscopy, electron, scanning |
4 |
|
mitochondrial transfer |
4 |
|
mortality |
4 |
|
nephrotoxicity |
4 |
|
neutrophils - physiology |
4 |
|
nicotine |
4 |
|
nicotinic acetylcholine receptor |
4 |
|
non-cystic fibrosis bronchiectasis |
4 |
|
non-diabetic men |
4 |
|
non-small cell lung cancer |
4 |
|
nsclc |
4 |
|
obesity - complications |
4 |
|
ofloxacin - administration & dosage - therapeutic use |
4 |
|
organizing pneumonia |
4 |
|
osa |
4 |
|
osimertinib |
4 |
|
oxidative stress - drug effects |
4 |
|
oxidoreductases - analysis - metabolism |
4 |
|
oxygen - metabolism |
4 |
|
palate, soft - pathology |
4 |
|
peritoneal dialysis - adverse effects - methods |
4 |
|
peritoneal dialysis, continuous ambulatory - adverse effects |
4 |
|
plasma dna |
4 |
|
polysomnography - methods |
4 |
|
pregnancy |
4 |
|
proliferation |
4 |
|
pseudomonas aeruginosa - drug effects - physiology |
4 |
|
psychometrics |
4 |
|
quantitative polymerase chain reaction |
4 |
|
randomised controlled trial |
4 |
|
respiratory system - pathology |
4 |
|
reverse transcriptase polymerase chain reaction |
4 |
|
rna, messenger - analysis |
4 |
|
salvage therapy |
4 |
|
second line chemotherapy |
4 |
|
serum |
4 |
|
severity of sleep disordered breathing |
4 |
|
silicosis |
4 |
|
silicosis - complications |
4 |
|
skull base - pathology |
4 |
|
sleep |
4 |
|
sleep apnea syndromes - blood - physiopathology |
4 |
|
sleep apnea syndromes - complications - epidemiology - therapy |
4 |
|
sleep apnea syndromes - etiology - prevention & control |
4 |
|
sleep apnea, central - diagnosis - prevention & control |
4 |
|
sleep apnea, obstructive - blood - diagnosis |
4 |
|
sleep apnea, obstructive - blood - physiopathology - therapy |
4 |
|
sleep apnea, obstructive - complications - pathology - physiopathology |
4 |
|
sleep apnea, obstructive - metabolism - therapy |
4 |
|
smoking - adverse effects |
4 |
|
socioeconomic factors |
4 |
|
sputum - microbiology |
4 |
|
stage i non-small cell carcinoma of lung |
4 |
|
stem cell factor |
4 |
|
streptococcus pneumoniae |
4 |
|
stress, psychological - epidemiology |
4 |
|
students, medical - psychology |
4 |
|
students, medical - statistics and numerical data |
4 |
|
students, nursing - psychology |
4 |
|
subminimal inhibitory concentration |
4 |
|
superoxide dismutase - analysis - metabolism |
4 |
|
survival outcomes |
4 |
|
teaching/methods |
4 |
|
time factors |
4 |
|
tongue - pathology |
4 |
|
transforming growth factor beta - metabolism |
4 |
|
transforming growth factor beta1 |
4 |
|
transforming growth factor-β1 |
4 |
|
treatment |
4 |
|
troponin |
4 |
|
tuberculosis, pulmonary - drug therapy - etiology - immunology - physiopathology - |
4 |
|
tumor necrosis factor-alpha - analysis - pharmacology |
4 |
|
tumor necrosis factor-α |
4 |
|
undergraduate |
4 |
|
urea - metabolism |
4 |
|
uremia - etiology - metabolism - pathology - therapy |
4 |
|
5-fluorouracil |
3 |
|
absorptiometry, photon |
3 |
|
acromegaly - complications - drug therapy - pathology |
3 |
|
activator appliances |
3 |
|
adenocarcinoma - ethnology - genetics |
3 |
|
adhesion molecules |
3 |
|
adipocyte fatty acid–binding protein |
3 |
|
administration, oral |
3 |
|
administration, topical |
3 |
|
aerosols |
3 |
|
ahi (apnea-hypopnea index) |
3 |
|
airway inflammation |
3 |
|
amino acid substitution |
3 |
|
amyloidosis - complications - metabolism - radiography |
3 |
|
androstadienes - administration & dosage - therapeutic use |
3 |
|
animals |
3 |
|
anti-bacterial agents - therapeutic use |
3 |
|
anti-infective agents - administration & dosage - therapeutic use |
3 |
|
anti-inflammatory agents - administration & dosage - therapeutic use |
3 |
|
anti-neutrophil cytoplasm auto-antibody (anca) |
3 |
|
antibodies, bacterial - blood |
3 |
|
antineoplastic agents - adverse effects |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
antioxidants |
3 |
|
arsenic trioxide |
3 |
|
arsenicals - adverse effects |
3 |
|
asia |
3 |
|
basic sciences |
3 |
|
beclomethasone - administration & dosage - adverse effects |
3 |
|
behavioral science |
3 |
|
bevacizumab |
3 |
|
biopsy |
3 |
|
bleeding |
3 |
|
blood glucose - metabolism |
3 |
|
bone marrow transplantation |
3 |
|
bone metastasis |
3 |
|
brain metastasis |
3 |
|
breast carcinoma |
3 |
|
bronchi - pathology |
3 |
|
bronchial neoplasms - diagnosis - pathology |
3 |
|
bronchiectasis - drug therapy |
3 |
|
bronchiectasis - drug therapy - immunology - microbiology - pathology |
3 |
|
bronchiectasis - immunology - microbiology |
3 |
|
bronchiectasis - pathology - radiography |
3 |
|
bronchodilator agents - administration & dosage - adverse effects |
3 |
|
bronchoscopy - methods |
3 |
|
budesonide |
3 |
|
c-reactive protein - metabolism |
3 |
|
capecitabine |
3 |
|
carcinoma - etiology |
3 |
|
carcinoma of lung |
3 |
|
carcinoma, non-small-cell lung - drug therapy |
3 |
|
carcinoma, non-small-cell lung - drug therapy - pathology - radiotherapy |
3 |
|
cardiac patient |
3 |
|
cardiovascular disease |
3 |
|
cardiovascular morbidity |
3 |
|
case report |
3 |
|
catalase - genetics - metabolism |
3 |
|
ceftazidime |
3 |
|
ceftazidime - administration & dosage - therapeutic use |
3 |
|
cephalosporins - administration & dosage - therapeutic use |
3 |
|
chrna7 |
3 |
|
cilia - ultrastructure |
3 |
|
clara cell protein |
3 |
|
clinical tool |
3 |
|
computed tomography |
3 |
|
confidence intervals |
3 |
|
conscious sedation |
3 |
|
conventional risk factors |
3 |
|
cpap adherence |
3 |
|
cpap therapy |
3 |
|
critical thinking |
3 |
|
cross-cultural comparison |
3 |
|
ct |
3 |
|
cysts |
3 |
|
cytokines |
3 |
|
daytime blood pressure |
3 |
|
dendrobium officinale |
3 |
|
dental occlusion |
3 |
|
deoxycytidine - analogs & derivatives - therapeutic use |
3 |
|
diabetes mellitus, type 2 - blood - complications - epidemiology |
3 |
|
diagnostic value |
3 |
|
e-selectin - blood |
3 |
|
education, medical, undergraduate |
3 |
|
elderly |
3 |
|
endothelium, vascular - physiopathology |
3 |
|
environmental exposure |
3 |
|
ess (epworth sleepiness scale) |
3 |
|
exacerbations |
3 |
|
face |
3 |
|
facial bones - pathology |
3 |
|
fatal outcome |
3 |
|
fibrosis |
3 |
|
fluorescence |
3 |
|
fluorouracil - analogs & derivatives - therapeutic use |
3 |
|
function silicosis |
3 |
|
functional residual capacity |
3 |
|
gene frequency |
3 |
|
genetic predisposition to disease - ethnology |
3 |
|
genetic susceptibility |
3 |
|
glutathione transferase - genetics |
3 |
|
glutathione-s-transferases |
3 |
|
great britain - epidemiology |
3 |
|
hba1c |
3 |
|
health facility administrators |
3 |
|
helicobacter infections - diagnosis - immunology |
3 |
|
helicobacter pylori - immunology - isolation & purification |
3 |
|
hospitalization - statistics & numerical data |
3 |
|
human bronchial epithelial cells |
3 |
|
hypertension - etiology - metabolism - physiopathology |
3 |
|
hypoxia |
3 |
|
image processing, computer-assisted |
3 |
|
injections, intravenous |
3 |
|
intercellular adhesion molecule-1 - blood |
3 |
|
intimate relationship |
3 |
|
kidney failure, chronic - complications - therapy |
3 |
|
leukaemia |
3 |
|
leukemia, promyelocytic, acute - drug therapy - physiopathology |
3 |
|
levofloxacin |
3 |
|
linguistic |
3 |
|
lung - pathology |
3 |
|
lung - physiopathology - radiography |
3 |
|
lung disease burden |
3 |
|
lung diseases - chemically induced - physiopathology |
3 |
|
lung diseases - complications - metabolism - radiography |
3 |
|
lung neoplasms - diagnosis |
3 |
|
lung neoplasms - drug therapy |
3 |
|
lung neoplasms - drug therapy - pathology - radiotherapy |
3 |
|
lung neoplasms - enzymology - ethnology - genetics |
3 |
|
lung neoplasms - epidemiology - genetics |
3 |
|
lung neoplasms - etiology |
3 |
|
lung nodules |
3 |
|
lymphoepithelioma |
3 |
|
lymphoepithelioma-like carcinoma |
3 |
|
lymphoma - etiology |
3 |
|
malignant pleural effusion |
3 |
|
malondialdehyde (mda) |
3 |
|
mandibular advancement - instrumentation |
3 |
|
mandibular advancement device |
3 |
|
maximal expiratory flow rate |
3 |
|
medical errors - prevention and control |
3 |
|
medical student |
3 |
|
microscopy, electron |
3 |
|
microtubules - ultrastructure |
3 |
|
neutrophils |
3 |
|
obstructive sleep apnea (osa) |
3 |
|
octreotide - therapeutic use |
3 |
|
odds ratio |
3 |
|
oncology |
3 |
|
oral appliances |
3 |
|
orthodontic appliance design |
3 |
|
orthodontics |
3 |
|
osteoporosis - chemically induced |
3 |
|
outcome |
3 |
|
oxides - adverse effects |
3 |
|
patient compliance |
3 |
|
patient education as topic |
3 |
|
pd-l1 |
3 |
|
pembrolizumab |
3 |
|
peritoneal dialysis |
3 |
|
peritoneal dialysis - methods |
3 |
|
peritoneal dialysis, continuous ambulatory |
3 |
|
pleural drainage |
3 |
|
pleurodesis |
3 |
|
polymorphisms |
3 |
|
polysaccharides |
3 |
|
positive-pressure respiration |
3 |
|
pre-invasive lesion |
3 |
|
pregnenediones - administration & dosage - adverse effects |
3 |
|
premenopause |
3 |
|
problem description |
3 |
|
problem identification |
3 |
|
professional skills |
3 |
|
proteinuria |
3 |
|
pulmonary |
3 |
|
pulmonary diffusing capacity - physiology |
3 |
|
pulmonary disease, chronic obstructive - blood - physiopathology |
3 |
|
pulmonary emphysema - physiopathology - radiography |
3 |
|
pulmonary fibrosis - physiopathology - radiography |
3 |
|
pulmonary function testing |
3 |
|
pulmonary hzemorrbage |
3 |
|
radiotherapy |
3 |
|
rct (randomized controlled trial) |
3 |
|
real patient |
3 |
|
residual volume |
3 |
|
respiratory tract diseases - epidemiology - mortality |
3 |
|
retrognathism |
3 |
|
risk |
3 |
|
risk assessment |
3 |
|
safety management |
3 |
|
screening |
3 |
|
secondary amyloidosis |
3 |
|
self-efficacy |
3 |
|
semirigid pleuroscopy |
3 |
|
serotonin |
3 |
|
severe obstructive sleep apnea |
3 |
|
side effects |
3 |
|
silicosis - physiopathology - radiography |
3 |
|
sjogren's syndrome |
3 |
|
sjogren's syndrome - complications |
3 |
|
sleep apnea syndromes - complications - drug therapy - pathology |
3 |
|
sleep apnea, obstructive - complications - metabolism - physiopathology |
3 |
|
sleep apnea, obstructive - diagnosis - epidemiology - etiology |
3 |
|
sleep apnea, obstructive - pathology - therapy |
3 |
|
sleep apnea, obstructive - therapy |
3 |
|
smoking - blood |
3 |
|
somatostatin - analogs & derivatives |
3 |
|
sputum - chemistry |
3 |
|
sputum - cytology - drug effects - immunology - microbiology |
3 |
|
sputum pathogens |
3 |
|
superoxide dismutase - blood - genetics - metabolism |
3 |
|
syndrome |
3 |
|
thoracentesis |
3 |
|
tissue inhibitor of metalloproteinase |
3 |
|
total lung capacity |
3 |
|
type 2 diabetes mellitus |
3 |
|
validation |
3 |
|
vascular cell adhesion molecule-1 - blood |
3 |
|
vasculitis |
3 |
|
vertical dimension |
3 |
|
(-)-epigallocatechin-3-gallate |
2 |
|
*medicine, chinese traditional history/trends |
2 |
|
5-hydroxytryptamine (5-ht) |
2 |
|
acetylcysteine |
2 |
|
actinomycetales infections - drug therapy - radiography |
2 |
|
activity |
2 |
|
adipocyte |
2 |
|
adipogenesis |
2 |
|
adipose inflammation |
2 |
|
adipose tissue |
2 |
|
adnexal diseases - complications - diagnosis |
2 |
|
adrenal cortex hormones - administration & dosage - therapeutic use |
2 |
|
adrenergic beta-agonists - therapeutic use |
2 |
|
adult-onset |
2 |
|
advanced glycation end products |
2 |
|
advanced oxidation protein products (aopp) |
2 |
|
age |
2 |
|
age distribution |
2 |
|
aging |
2 |
|
aging - metabolism |
2 |
|
airway epithelium |
2 |
|
alleles |
2 |
|
alpha 1-antitrypsin - metabolism |
2 |
|
anaplastic lymphoma kinase |
2 |
|
anemia, hemolytic, autoimmune - diagnosis - drug therapy |
2 |
|
animal experiment |
2 |
|
animal modelanimal tissue |
2 |
|
anoxia - complications - diagnosis - physiopathology |
2 |
|
anti-bacterial agents |
2 |
|
antioxidant |
2 |
|
anxiety - epidemiology |
2 |
|
aortic endothelial cells |
2 |
|
arthritis, rheumatoid - pathology |
2 |
|
asian continental ancestry group - statistics & numerical data |
2 |
|
asian continental ancestry group/*genetics |
2 |
|
asians |
2 |
|
asthma - blood - drug therapy |
2 |
|
asthma - blood - genetics |
2 |
|
asthma - drug therapy - physiopathology |
2 |
|
asthma - enzymology - epidemiology - genetics |
2 |
|
asthma - epidemiology - physiopathology |
2 |
|
asthma - epidemiology - prevention & control - psychology |
2 |
|
asthma - genetics |
2 |
|
asthma - metabolism |
2 |
|
atherogenesis |
2 |
|
atherosclerosis - blood - etiology |
2 |
|
atopy |
2 |
|
bacterial infections - epidemiology |
2 |
|
bal |
2 |
|
binding sites |
2 |
|
blotting, western |
2 |
|
body constitution |
2 |
|
body surface area |
2 |
|
bone loss |
2 |
|
bone marrow transplant |
2 |
|
bone metabolism |
2 |
|
bone mineral density |
2 |
|
brachial artery - physiopathology |
2 |
|
breath tests - instrumentation |
2 |
|
bronchiectasis - drug therapy - enzymology - physiopathology |
2 |
|
bronchiectasis - enzymology |
2 |
|
bronchiectasis - enzymology - immunology - physiopathology |
2 |
|
bronchoalveolar lavage |
2 |
|
bronchoalveolar lavage fluid - chemistry |
2 |
|
calcium - administration & dosage - blood |
2 |
|
calgary sleep apnea quality of life index (saqli) |
2 |
|
cardiomyocytes |
2 |
|
catalase - blood |
2 |
|
catalase - genetics |
2 |
|
cell damage |
2 |
|
cell line |
2 |
|
cephalometry - methods |
2 |
|
cesarean section |
2 |
|
chemotaxis, leukocyte - drug effects |
2 |
|
chi-square distribution |
2 |
|
chinese population |
2 |
|
cholesterol |
2 |
|
cholesterol, hdl - blood |
2 |
|
chondroitin sulfates - metabolism |
2 |
|
chronic obstructive lung disease |
2 |
|
chronic obstructive pulmonary disease (copd) |
2 |
|
cigarette smoke (cs) |
2 |
|
cigarette smoke medium |
2 |
|
circulating tumor dna (ctdna) |
2 |
|
clinical medicine - education |
2 |
|
clinical medicine/*education/history/trends |
2 |
|
craniofacial abnormalities - complications |
2 |
|
culture |
2 |
|
cytokine-induced neutrophil chemoattractant-1 (cinc-1) |
2 |
|
cytokines - immunology |
2 |
|
cytomegalovirus infections - epidemiology |
2 |
|
diagnosis |
2 |
|
diet |
2 |
|
dinoprost - analogs & derivatives - blood |
2 |
|
discriminant analysis |
2 |
|
disease association |
2 |
|
disease control rate |
2 |
|
disease severity |
2 |
|
disease transmission, patient-to-professional - prevention & control |
2 |
|
drainage |
2 |
|
drug therapy - trends |
2 |
|
drug therapy, combination - therapeutic use |
2 |
|
education, medical - history - organization & administration - trends |
2 |
|
education, medical/*organisation & administration/history/trends |
2 |
|
environmental tobacco smoke |
2 |
|
enzyme linked immunosorbent assay |
2 |
|
epidermal growth factor receptor (egfr) |
2 |
|
epidermal growth factor receptor tyrosine kinase inhibitors |
2 |
|
epigallocatechin gallate |
2 |
|
erlotinib |
2 |
|
erythrocyte |
2 |
|
ethnic groups/*statistics & numerical data |
2 |
|
etidronate |
2 |
|
evan's syndrome |
2 |
|
exhaled nitric oxide |
2 |
|
extracellular vesicles |
2 |
|
family history |
2 |
|
family practice |
2 |
|
fatty acid-binding protein |
2 |
|
fiber optic technology |
2 |
|
fission |
2 |
|
flow-mediated dilation |
2 |
|
forecasting |
2 |
|
free radical scavengers |
2 |
|
gastroesophageal reflux - epidemiology - psychology |
2 |
|
gender |
2 |
|
gene frequency/genetics |
2 |
|
genetic background |
2 |
|
genetic polymorphism |
2 |
|
genetic predisposition to disease - genetics |
2 |
|
genetic variation/genetics |
2 |
|
glucocorticoids - administration and dosage - therapeutic use |
2 |
|
glucocorticoids - therapeutic use |
2 |
|
glutathione disulfide - blood |
2 |
|
glutathione disulfide, or oxidized gsh |
2 |
|
glutathione peroxidase - blood |
2 |
|
glutathione s-transferase |
2 |
|
glutathione transferase - blood - genetics |
2 |
|
glutathione transferase - physiology |
2 |
|
gpx |
2 |
|
gsh |
2 |
|
gssg |
2 |
|
haeme oxygenase-1 |
2 |
|
haemin |
2 |
|
hb |
2 |
|
hdl dysfunction |
2 |
|
health personnel |
2 |
|
health-related quality of life (hrqol) |
2 |
|
hemoglobin |
2 |
|
heparan sulfate proteoglycans |
2 |
|
heparin |
2 |
|
heparitin sulfate - metabolism |
2 |
|
high resolution computed tomography |
2 |
|
hippo |
2 |
|
histocompatibility testing |
2 |
|
history of medicine |
2 |
|
history, 15th century |
2 |
|
history, 16th century |
2 |
|
history, 17th century |
2 |
|
history, 18th century |
2 |
|
history, 19th century |
2 |
|
history, 20th century |
2 |
|
history, ancient |
2 |
|
history, medieval |
2 |
|
hla antigens - analysis |
2 |
|
hla antigens/genetics |
2 |
|
hla-b antigens/genetics |
2 |
|
hla-dr antigens/*genetics |
2 |
|
hong kong - ethnology |
2 |
|
hong kong chinese population |
2 |
|
hong kong/epidemiology |
2 |
|
human |
2 |
|
hyoid bone - radiography |
2 |
|
hypercholesterolemia - blood - complications |
2 |
|
hypertension - diagnosis - ethnology |
2 |
|
immunoglobulin enhancer binding protein |
2 |
|
independently associated |
2 |
|
india |
2 |
|
infection - epidemiology |
2 |
|
infection control - organization & administration |
2 |
|
inflammation |
2 |
|
inhaled corticosteroids |
2 |
|
insecticide |
2 |
|
intensive care |
2 |
|
interleukin-4 |
2 |
|
interleukin-4 - genetics |
2 |
|
interleukin-4 receptor |
2 |
|
interleukin-4 receptor alpha subunit - genetics |
2 |
|
intermittent hypoxia (ih) |
2 |
|
interviews as topic |
2 |
|
intratumoural heterogeneity |
2 |
|
intravascular lymphomatosis |
2 |
|
kartagener's syndrome |
2 |
|
large tumour suppressor (lats) |
2 |
|
learning |
2 |
|
leptin |
2 |
|
leptin - blood |
2 |
|
letter |
2 |
|
leukocyte elastase - metabolism |
2 |
|
longitudinal assessment |
2 |
|
luminescent measurements |
2 |
|
lung - metabolism |
2 |
|
lung abscess |
2 |
|
lung abscess - drug therapy - radiography |
2 |
|
lung diseases - epidemiology |
2 |
|
lung diseases, fungal - epidemiology |
2 |
|
lung diseases, interstitial - etiology - radiography |
2 |
|
lung diseases, obstructive - diagnosis - epidemiology - etiology |
2 |
|
lung neoplasms - epidemiology - etiology |
2 |
|
lupus erythematosus, systemic - complications |
2 |
|
lymphangioleiomyomatosis |
2 |
|
lymphangioleiomyomatosis - complications - diagnosis |
2 |
|
lymphoma, t-cell - complications - pathology - therapy |
2 |
|
lymphotoxin-alpha - genetics |
2 |
|
lymphotoxin-α |
2 |
|
macrophages |
2 |
|
mandible - radiography |
2 |
|
mechanistic pathway |
2 |
|
medicine, chinese traditional - history - trends |
2 |
|
membrane glycoproteins - metabolism |
2 |
|
metabolic syndrome x - physiology |
2 |
|
metabolic variates |
2 |
|
middle-aged chinese men |
2 |
|
middle-aged chinese women |
2 |
|
mitochondria |
2 |
|
monoamine oxidase |
2 |
|
monoamine oxidase (mao) |
2 |
|
monoamine oxidase-b |
2 |
|
mucus secretion |
2 |
|
myasthenia gravis |
2 |
|
myasthenia gravis - classification - genetics - immunology |
2 |
|
myasthenia gravis - drug therapy - surgery |
2 |
|
myasthenia gravis/diagnosis/*epidemiology/genetics |
2 |
|
myasthenia gravis/epidemiology/*genetics |
2 |
|
nasal cavity - radiography |
2 |
|
nasal continuous positive airway pressure (cpap) |
2 |
|
nebulizers and vaporizers |
2 |
|
necrosis |
2 |
|
neurologic examination |
2 |
|
neutrophil |
2 |
|
neutrophil elastase |
2 |
|
neutrophil infiltration |
2 |
|
neutrophils - enzymology |
2 |
|
nf-κb |
2 |
|
nitric oxide - analysis |
2 |
|
obesity - epidemiology - etiology - physiopathology |
2 |
|
obstetrical forceps |
2 |
|
occupational exposure |
2 |
|
oculomotor muscles |
2 |
|
opportunistic infections - drug therapy - radiography |
2 |
|
oxidative stress - genetics |
2 |
|
oxidative stress - physiology |
2 |
|
oxidized glutathione |
2 |
|
pancreatic elastase - analysis |
2 |
|
patient acceptance of health care |
2 |
|
pharynx - radiography |
2 |
|
plasma |
2 |
|
pleural diseases - etiology - radiography |
2 |
|
pneumonia - epidemiology |
2 |
|
pneumonia - etiology |
2 |
|
pneumothorax - therapy |
2 |
|
pneumothorax/surgery |
2 |
|
polymerase chain reaction |
2 |
|
polymorphism |
2 |
|
polymorphism, genetic - genetics |
2 |
|
polymorphism, restriction fragment length |
2 |
|
polymyositis - complications |
2 |
|
polysaccharide-lyases - metabolism |
2 |
|
polysomnography - statistics & numerical data |
2 |
|
posture |
2 |
|
prednisolone - therapeutic use |
2 |
|
pregnancy complications - surgery |
2 |
|
pregnancy complications - surgery - therapy |
2 |
|
priority journal |
2 |
|
programmed death‐ligand 1 |
2 |
|
protein binding |
2 |
|
proteinase |
2 |
|
proteinase inhibitory proteins, secretory |
2 |
|
proteins - metabolism |
2 |
|
proteoglycans - metabolism |
2 |
|
public health |
2 |
|
pulmonary diffusing capacity |
2 |
|
pulmonary disease, chronic obstructive - blood - genetics - physiopathology |
2 |
|
pulmonary disease, chronic obstructive - enzymology - ethnology - genetics |
2 |
|
pulmonary gas exchange |
2 |
|
pulmonary infections |
2 |
|
pulmonary medicine |
2 |
|
pyridostigmine bromide - therapeutic use |
2 |
|
quinazolines - therapeutic use |
2 |
|
radioimmunoassay |
2 |
|
rats |
2 |
|
rats, sprague-dawley |
2 |
|
reactive oxygen species |
2 |
|
receptors, cholinergic - immunology |
2 |
|
receptors, cholinergic/*immunology |
2 |
|
recombinant proteins - metabolism |
2 |
|
reduced glutathione |
2 |
|
reference value |
2 |
|
reproducibility of results |
2 |
|
respiration disorders - etiology - physiopathology - radiography |
2 |
|
respiratory infections |
2 |
|
rheumatoid nodule - pathology |
2 |
|
rhinitis |
2 |
|
rhinitis, allergic, perennial - drug therapy - epidemiology |
2 |
|
rhinitis, allergic, seasonal - drug therapy - epidemiology |
2 |
|
rhodococcus equi |
2 |
|
rhodococcus equi - isolation & purification |
2 |
|
risk factor |
2 |
|
salvage therapy - methods |
2 |
|
secretory leukoproteinase inhibitor |
2 |
|
selegiline |
2 |
|
serine proteinase inhibitors - metabolism |
2 |
|
sex characteristics |
2 |
|
sex distribution |
2 |
|
sleep apnea syndrome |
2 |
|
sleep apnea syndromes - complications - diagnosis |
2 |
|
sleep apnea syndromes - diagnosis - epidemiology |
2 |
|
sleep apnea syndromes - ethnology - physiopathology - radiography |
2 |
|
sleep apnea, obstructive - blood - complications |
2 |
|
sleep apnea, obstructive - blood - complications - therapy |
2 |
|
sleep apnea, obstructive - complications - epidemiology - ethnology - therapy |
2 |
|
sleep apnea, obstructive - complications - epidemiology - physiopathology |
2 |
|
sleep apnea, obstructive - diagnosis - ethnology |
2 |
|
sleep apnea, obstructive - diagnosis - therapy |
2 |
|
sleep apnea, obstructive - ethnology - psychology - rehabilitation |
2 |
|
sleep apnoea |
2 |
|
sleep disordered breathing |
2 |
|
sleep studies |
2 |
|
smoking - epidemiology - genetics |
2 |
|
smoking - genetics |
2 |
|
smoking - genetics - metabolism |
2 |
|
snoring - etiology |
2 |
|
socioeconomic factor |
2 |
|
spectrophotometry |
2 |
|
sputum - cytology - drug effects - enzymology |
2 |
|
sputum - enzymology |
2 |
|
sputum - immunology |
2 |
|
steroids - therapeutic use |
2 |
|
superoxide anion |
2 |
|
superoxide dismutase - blood |
2 |
|
superoxide dismutase - genetics |
2 |
|
surface plasmon resonance |
2 |
|
survival analysis |
2 |
|
syndecan-1 |
2 |
|
syndecan-1 - genetics - metabolism |
2 |
|
syndecans |
2 |
|
systemic inflammatory response syndrome |
2 |
|
systemic inflammatory response syndrome - etiology |
2 |
|
teaching - history - methods |
2 |
|
thigh - blood supply |
2 |
|
thoracic medicine |
2 |
|
thoracic surgery, video-assisted |
2 |
|
threonine-trna ligase - immunology |
2 |
|
thrombocytopenia - diagnosis - drug therapy |
2 |
|
thymectomy |
2 |
|
thymoma/diagnosis/epidemiology/genetics |
2 |
|
thymus neoplasms/diagnosis/epidemiology/genetics |
2 |
|
tki-resistance |
2 |
|
tongue - radiography |
2 |
|
tracheal diseases - pathology |
2 |
|
transfection |
2 |
|
transforming growth factor beta - genetics |
2 |
|
transforming growth factor beta1 - blood - genetics |
2 |
|
tspo |
2 |
|
tuberculosis, pulmonary - epidemiology |
2 |
|
tumor burden |
2 |
|
tumor necrosis factor-alpha - genetics |
2 |
|
vascular diseases - blood - etiology - prevention & control |
2 |
|
vascular diseases - complications - pathology - therapy |
2 |
|
vascular reactivity |
2 |
|
vascular resistance - physiology |
2 |
|
vascular risks |
2 |
|
vasodilation |
2 |
|
venous insufficiency - etiology |
2 |
|
world health |
2 |
|
α1-antitrypsin |
2 |
|
1,25-dihydroxycholecalciferol |
1 |
|
absorption |
1 |
|
activities of daily living |
1 |
|
adrenergic beta-agonists - administration & dosage |
1 |
|
adrenergic beta-agonists - administration & dosage - therapeutic use |
1 |
|
advanced non-small cell lung cancer |
1 |
|
aerosol |
1 |
|
africa - epidemiology |
1 |
|
air pollution |
1 |
|
air pollution - adverse effects |
1 |
|
albuterol - administration & dosage |
1 |
|
alpha 1-antitrypsin - analysis |
1 |
|
amoxicillin - administration & dosage - therapeutic use |
1 |
|
anesthesia |
1 |
|
anoxia - physiopathology |
1 |
|
anti-asthmatic agents - administration & dosage |
1 |
|
anti-asthmatic agents - administration & dosage - therapeutic use |
1 |
|
anti-asthmatic drug utilization |
1 |
|
antibody-producing cells - immunology |
1 |
|
antineoplastic agents/therapeutic user |
1 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - therapeutic use |
1 |
|
apical pulmonary disease |
1 |
|
arachidonic acid |
1 |
|
arachidonic acids - physiology |
1 |
|
artery disease |
1 |
|
artificial organs |
1 |
|
asbestos - toxicity |
1 |
|
asia pacific |
1 |
|
asia-pacific |
1 |
|
asian continental ancestry group - ethnology |
1 |
|
aspergillosis, allergic bronchopulmonary - diagnosis |
1 |
|
asthma - blood - physiopathology - radionuclide imaging |
1 |
|
asthma - complications - diagnosis |
1 |
|
asthma - diagnosis - epidemiology |
1 |
|
asthma - epidemiology |
1 |
|
asthma - etiology |
1 |
|
asthma - mortality |
1 |
|
asthma - mortality - prevention & control |
1 |
|
asthma mortality |
1 |
|
australia |
1 |
|
australia - epidemiology |
1 |
|
autonomic nervous system - physiopathology |
1 |
|
bacteria - isolation & purification |
1 |
|
bacterial infections - drug therapy - microbiology |
1 |
|
bacteriological techniques |
1 |
|
biology |
1 |
|
biomedical ethics |
1 |
|
breast reconstruction complications |
1 |
|
british columbia - epidemiology |
1 |
|
bronchi - drug effects - physiopathology |
1 |
|
bronchi - physiopathology |
1 |
|
bronchial |
1 |
|
bronchial diseases - diagnosis - drug therapy |
1 |
|
bronchial provocation tests |
1 |
|
bronchial reactivity |
1 |
|
bronchiectasis - complications - physiopathology |
1 |
|
bronchiectasis - diagnosis - epidemiology |
1 |
|
bronchiectasis - diagnosis - epidemiology - physiopathology |
1 |
|
bronchiectasis - diagnosis - therapy |
1 |
|
bronchiectasis - drug therapy - microbiology |
1 |
|
bronchiectasis - epidemiology |
1 |
|
bronchiolitis - ethnology |
1 |
|
bronchiolitis - ethnology - physiopathology - radiography |
1 |
|
bronchiolitis obliterans |
1 |
|
bronchiolitis obliterans - etiology - physiopathology - radiography |
1 |
|
bronchoconstriction - drug effects |
1 |
|
bronchoconstriction - physiology |
1 |
|
bronchodilator agents |
1 |
|
bronchodilator agents - administration & dosage |
1 |
|
bronchodilator agents - administration & dosage - therapeutic use |
1 |
|
bronchodilators |
1 |
|
bronchography |
1 |
|
calcinosis - etiology - radiography - surgery |
1 |
|
calcitriol - administration & dosage - blood - pharmacology |
1 |
|
calcium - metabolism |
1 |
|
calcium channel blockers - pharmacology - therapeutic use |
1 |
|
calcium-channel blockers |
1 |
|
carcinoma, bronchogenic - pathology - secondary |
1 |
|
carcinoma, non-small-cell lung - complications - drug therapy - secondary |
1 |
|
carcinoma, non-small-cell lung - drug therapy - mortality - pathology |
1 |
|
carcinoma, non-small-cell lung - secondary |
1 |
|
carcinoma, non-small-cell lung/drug therapy |
1 |
|
cardiovascular diseases - epidemiology |
1 |
|
cell adhesion |
1 |
|
cell movement - drug effects |
1 |
|
cerebrovascular accident |
1 |
|
challenge |
1 |
|
chemotactic factors - physiology |
1 |
|
chemotaxis - drug effects |
1 |
|
chinese adults |
1 |
|
chronic bronchial sepsis |
1 |
|
chronic bronchitis |
1 |
|
cinnarizine - therapeutic use |
1 |
|
cisplatin |
1 |
|
cisplatin - administration & dosage |
1 |
|
cisplatinum |
1 |
|
clinical competence |
1 |
|
confounding factors (epidemiology) |
1 |
|
confusion - chemically induced - prevention & control |
1 |
|
congential vertebral anomalies |
1 |
|
constriction, pathologic - diagnosis |
1 |
|
continuous ambulatory peritoneal dialysis |
1 |
|
controlled comparison |
1 |
|
coronary |
1 |
|
critical care |
1 |
|
cystic fibrosis - diagnosis - physiopathology - therapy |
1 |
|
cytokines - metabolism |
1 |
|
decision making |
1 |
|
delivery of health care - standards |
1 |
|
demographic factors |
1 |
|
deoxycytidine/analogs and derivatives |
1 |
|
depression - etiology |
1 |
|
dermatomyositis - drug therapy - etiology |
1 |
|
developing countries |
1 |
|
developing countries - statistics & numerical data |
1 |
|
diabetes complications |
1 |
|
diabetes mellitus |
1 |
|
diabetes mellitus - epidemiology |
1 |
|
diabetes mellitus - metabolism |
1 |
|
diabetes mellitus, type 2 - epidemiology - prevention & control |
1 |
|
diabetes mellitus, type 2 - metabolism |
1 |
|
diabetucs, |
1 |
|
diaphragm |
1 |
|
diaphragm - physiology |
1 |
|
diaphragmatic function |
1 |
|
diffuse panbronchiolitis |
1 |
|
diskhaler |
1 |
|
disorders in glucose metabolism |
1 |
|
disseminated intravascular coagulation - chemically induced |
1 |
|
dogs |
1 |
|
dose response |
1 |
|
electric stimulation therapy |
1 |
|
endothelial dysfunction |
1 |
|
environmental pollution |
1 |
|
epidemiologic research design |
1 |
|
epithelium - physiopathology |
1 |
|
equipment design |
1 |
|
erythromycin - therapeutic use |
1 |
|
ethics, medical |
1 |
|
ethnicity |
1 |
|
european continental ancestry group - ethnology |
1 |
|
exhalation - physiology |
1 |
|
face - pathology |
1 |
|
family |
1 |
|
fatty acid-binding proteins - physiology |
1 |
|
forced expiratory volume - drug effects |
1 |
|
foreign-body migration - radiography - surgery |
1 |
|
foreign-body reaction - radiography - surgery |
1 |
|
free radicals - metabolism |
1 |
|
functional residual capacity - drug effects |
1 |
|
futility |
1 |
|
global initiative for chronic obstructive lung disease statement |
1 |
|
glucose metabolism |
1 |
|
graft-versus-host disease |
1 |
|
gram-negative rod |
1 |
|
growth and development |
1 |
|
guinea pigs |
1 |
|
headache - etiology |
1 |
|
hemodynamics |
1 |
|
hemolytic plaque technique |
1 |
|
high-resolution computed tomography |
1 |
|
histamine |
1 |
|
histamine - diagnostic use |
1 |
|
histamine release |
1 |
|
hiv seropositivity |
1 |
|
hong kong, critical care in |
1 |
|
hospitalization - trends |
1 |
|
hypertension - complications |
1 |
|
hypertension - epidemiology |
1 |
|
hypertension - epidemiology - etiology |
1 |
|
ifosfamide - administration & dosage |
1 |
|
immune tolerance |
1 |
|
immunoglobulins - analysis |
1 |
|
individual autonomy |
1 |
|
indoor air pollution predictive model |
1 |
|
infectious diseases |
1 |
|
inflammation - blood |
1 |
|
inflammation - etiology |
1 |
|
inflammation - etiology - physiopathology |
1 |
|
influenza vaccination |
1 |
|
influenza vaccines |
1 |
|
informed consent |
1 |
|
inhalation |
1 |
|
inhaled steroids |
1 |
|
injections, intraperitoneal |
1 |
|
intemittent hypoxia |
1 |
|
international cooperation |
1 |
|
ion channels - physiology |
1 |
|
ischemic heart disease |
1 |
|
isoniazid - adverse effects |
1 |
|
isoniazid - therapeutic use |
1 |
|
japan - ethnology |
1 |
|
kidney failure, chronic - complications |
1 |
|
kidney failure, chronic - drug therapy - physiopathology - therapy |
1 |
|
kidney failure, chronic - metabolism - therapy |
1 |
|
knowledge |
1 |
|
leukocyte count |
1 |
|
life support |
1 |
|
lipids - blood |
1 |
|
lower limit of normal |
1 |
|
lung - physiology |
1 |
|
lung - radionuclide imaging |
1 |
|
lung diseases - diagnosis - epidemiology |
1 |
|
lung diseases - virology |
1 |
|
lung function test |
1 |
|
lung function testing |
1 |
|
lung neoplasms - complications - drug therapy |
1 |
|
lung neoplasms - complications - pathology |
1 |
|
lung neoplasms - diagnosis - etiology - pathology |
1 |
|
lung neoplasms - drug therapy - epidemiology - pathology |
1 |
|
lung neoplasms - drug therapy - mortality - pathology |
1 |
|
lymph - drug effects - physiology |
1 |
|
lymph - metabolism |
1 |
|
lymphatic absorption |
1 |
|
lymphatic system - physiology |
1 |
|
macrolides |
1 |
|
macrophages - drug effects - physiology |
1 |
|
macrophages - physiology |
1 |
|
mammaplasty - adverse effects |
1 |
|
mandible |
1 |
|
mast cells - metabolism |
1 |
|
mast cells - physiology |
1 |
|
mastectomy |
1 |
|
mastitis - etiology - radiography - surgery |
1 |
|
mdi |
1 |
|
medical decision- making |
1 |
|
meningeal neoplasms - secondary |
1 |
|
metabolic syndrome x - epidemiology - etiology - metabolism |
1 |
|
metabolic syndrome x - etiology - metabolism - physiopathology |
1 |
|
metabolism -- disorders. |
1 |
|
metered-dose inhalers |
1 |
|
methacholine |
1 |
|
methacholine chloride - diagnostic use |
1 |
|
microbial sensitivity tests |
1 |
|
mitomycin - administration & dosage |
1 |
|
mortality - trends |
1 |
|
multivariate analysis |
1 |
|
muscle, smooth - physiopathology |
1 |
|
myasthenia gravis - complications |
1 |
|
mycobacterium tuberculosis - isolation & purification |
1 |
|
nifedipine - therapeutic use |
1 |
|
nitrates - blood |
1 |
|
nitric oxide - blood |
1 |
|
nitric oxide - physiology |
1 |
|
nitric oxide synthase - physiology |
1 |
|
nitrites - blood |
1 |
|
nose |
1 |
|
obesity - complications - epidemiology |
1 |
|
obstructive |
1 |
|
obstructive airways disease |
1 |
|
occupational diseases - chemically induced - drug therapy |
1 |
|
opportunistic infections - etiology |
1 |
|
oral appliance |
1 |
|
oxygen - blood |
1 |
|
pacific islands - epidemiology |
1 |
|
paclitaxel |
1 |
|
palliative care |
1 |
|
pandemics |
1 |
|
paraffin - adverse effects |
1 |
|
paraffinomas |
1 |
|
pathogenesis |
1 |
|
patient |
1 |
|
patient advocacy |
1 |
|
peak expiratory flow rate |
1 |
|
performance |
1 |
|
peritoneal cavity - physiology |
1 |
|
peritoneal macrophage chemotaxis |
1 |
|
peritoneum - physiology |
1 |
|
pharyngeal diseases - ethnology - pathology - radiography |
1 |
|
pharynx - pathology |
1 |
|
pharynx - pathology - radiography |
1 |
|
phosphatidylcholine |
1 |
|
phosphatidylcholines - administration & dosage - therapeutic use |
1 |
|
physical exertion |
1 |
|
physical therapy modalities |
1 |
|
physician |
1 |
|
physician's role |
1 |
|
physicians |
1 |
|
physiology pharmacy and pharmacology |
1 |
|
platelet activating factor - physiology |
1 |
|
pneumonia |
1 |
|
positive-pressure respiration - methods |
1 |
|
postoperative complications - radiography |
1 |
|
posture - physiology |
1 |
|
practical prevention |
1 |
|
predicted values |
1 |
|
pulmonary alveoli - physiopathology |
1 |
|
pulmonary disease, chronic obstructive - diagnosis - epidemiology - immunology - therapy |
1 |
|
pulmonary disease, chronic obstructive - diagnosis - epidemiology - therapy |
1 |
|
pulmonary disease, chronic obstructive - diagnosis - prevention & control - rehabilitation - therapy |
1 |
|
pulmonary disease, chronic obstructive - epidemiology - mortality |
1 |
|
pulmonary edema - chemically induced - drug therapy |
1 |
|
pulmonary function |
1 |
|
pulmonary melioidosis |
1 |
|
pulmonary rehabilitation |
1 |
|
pyridoxine - therapeutic use |
1 |
|
quadriplegia |
1 |
|
quadriplegia - rehabilitation |
1 |
|
radionuclide |
1 |
|
randomized controlled trials as topic |
1 |
|
regional |
1 |
|
renal dialysis |
1 |
|
respiration |
1 |
|
respiration disorders - etiology |
1 |
|
respiration, artificial |
1 |
|
respiratory function tests - standards |
1 |
|
respiratory insufficiency - etiology - therapy |
1 |
|
respiratory tract diseases - epidemiology |
1 |
|
respiratory tract infections - etiology |
1 |
|
restrictive pulmonary function |
1 |
|
ribs - radiography |
1 |
|
rifampin - adverse effects |
1 |
|
salbutamol |
1 |
|
self administration |
1 |
|
sequelae |
1 |
|
serum albumin - analysis |
1 |
|
serum globulins - analysis |
1 |
|
severe acute respiratory syndrome - complications - diagnosis - mortality - therapy |
1 |
|
severe acute respitory syndrome |
1 |
|
severe osa |
1 |
|
sheep |
1 |
|
sitting height |
1 |
|
skin tests |
1 |
|
skull - pathology |
1 |
|
skull - radiography |
1 |
|
sleep apnea syndromes - metabolism |
1 |
|
sleep apnea syndromes. |
1 |
|
sleep apnea, obstructive - blood - diagnosis - therapy |
1 |
|
sleep apnea, obstructive - complications - epidemiology - metabolism |
1 |
|
sleep apnea, obstructive - complications - epidemiology - physiopathology - therapy |
1 |
|
sleep apnea, obstructive - ethnology - pathology |
1 |
|
sleep apnea, obstructive - ethnology - pathology - radiography |
1 |
|
sleep apnea, obstructive - etiology |
1 |
|
sleep apnea, obstructive - etiology - metabolism - therapy |
1 |
|
sleep apnea, obstructive - metabolism - physiopathology - therapy |
1 |
|
sleep apnea, obstructive - pathology - physiopathology - radiography |
1 |
|
sleep apnoea syndrome |
1 |
|
sleep deprivation - physiopathology |
1 |
|
sleep disorders (respiratory medicine) |
1 |
|
sleep disorders - complications - epidemiology - physiopathology - therapy |
1 |
|
sleep stages - physiology |
1 |
|
sleep-disordered breathing |
1 |
|
smokers |
1 |
|
smoking - epidemiology |
1 |
|
solute transfer |
1 |
|
spinal cord injuries |
1 |
|
statistical modelling |
1 |
|
steroids |
1 |
|
stroke - epidemiology |
1 |
|
sulfuric acid esters - poisoning |
1 |
|
sulfuric acids - poisoning |
1 |
|
surgical treatment |
1 |
|
survival rate |
1 |
|
thorax |
1 |
|
thymectomy - adverse effects |
1 |
|
thyroid disease |
1 |
|
tobacco |
1 |
|
tomography, x-ray computed - methods |
1 |
|
tracheal diseases - diagnosis - drug therapy |
1 |
|
transcription, genetic - physiology |
1 |
|
triage |
1 |
|
tropical disease |
1 |
|
truth disclosure |
1 |
|
tuberculosis - complications |
1 |
|
tuberculosis, osteoarticular - complications - radiography |
1 |
|
tuberculosis, osteoarticular - immunology - radiography - therapy |
1 |
|
tuberculosis, pleural - complications - radiography |
1 |
|
tuberculosis, pulmonary - complications - radiography |
1 |
|
tuberculosis, pulmonary - diagnosis - drug therapy |
1 |
|
tuberculosis, pulmonary - diagnosis - epidemiology |
1 |
|
tuberculosis, pulmonary - diagnosis - microbiology |
1 |
|
tuberculosis, pulmonary - drug therapy |
1 |
|
ultrafiltration |
1 |
|
undiagnosed airflow obstruction |
1 |
|
united states - epidemiology |
1 |
|
upper airway |
1 |
|
upper airway morphology |
1 |
|
vaccination |
1 |
|
vagus nerve - physiopathology |
1 |
|
ventilation |
1 |
|
ventilator-associated pneumonia |
1 |
|
verapamil - therapeutic use |
1 |
|
vital capacity - physiology |
1 |
|
with-holding |
1 |
|
withdrawing |
1 |
|
z-score |
1 |
